The choice depends on your research needs and target concentration
As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
In clinical trials, nausea, vomiting, diarrhoea, and constipation were among the most common complaints, particularly during dose escalation phases
Tovar Jimnez, X., Arana Cuenca, A., TllezJurado, A., et al
Contenido: 90 Caps